Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?

被引：20

作者：

Drexel, Heinz ^{[1
]}

Tamargo, Juan ^{[2
]}

Kaski, Juan Carlos ^{[3
]}

Lewis, Basil S. ^{[4
]}

Saely, Christoph H. ^{[1
]}

Fraunberger, Peter ^{[5
]}

Dobrev, Dobromir ^{[6
,7
,8
,9
]}

Komiyama, Maki ^{[10
]}

Plattner, Thomas ^{[1
]}

Agewall, Stefan ^{[11
,12
]}

Hasegawa, Koji ^{[10
]}

机构：

[1] Vorarlberg Inst Vasc Invest & Treatment VIVIT, Vorarlberg, Austria

[2] Univ Complutense, Sch Med, Dept Pharmacol & Toxicol, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

[3] St Georges Univ London, Mol & Clin Sci Res Inst, London, England

[4] Technion Israel Inst Technol, Ruth & Bruce Rappaport Sch Med, Haifa, Israel

[5] Acad Teaching Hosp Feldkirch, Med Cent Labs, Feldkirch, Austria

[6] Univ Duisburg Essen, Inst Pharmacol, Fac Med, Essen, Germany

[7] Montreal Heart Inst, Med & Res Ctr, Montreal, PQ, Canada

[8] Univ Montreal, Montreal, PQ, Canada

[9] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX USA

[10] Natl Hosp Org Kyoto Med Ctr, Div Translat Res, Kyoto, Japan

[11] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden

[12] Univ Oslo, Inst Clin Med, Oslo, Norway

来源：

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2023年 / 9卷 / 06期

关键词：

Atherosclerosis; Cardiovascular disease; Hypertriglyceridaemia; Lipoprotein; Lipid-lowering therapy; Statins; CORONARY-ARTERY-DISEASE; EICOSAPENTAENOIC ACID; STATIN THERAPY; CHOLESTEROL REDUCTION; PRIMARY-PREVENTION; RICH LIPOPROTEINS; RISK REDUCTION; EVENTS; ATHEROSCLEROSIS; METAANALYSIS;

D O I：

10.1093/ehjcvp/pvad044

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Despite the atherosclerotic cardiovascular disease (ASCVD) risk reduction achieved by low-density lipoprotein cholesterol (LDL-C) lowering therapy, residual ASCVD risk still exists. Previous epidemiological studies have suggested high plasma triglyceride (TG) levels as a risk factor or risk marker for ASCVD independent of LDL-C levels. In this review, we highlighted the underlying pathophysiology of hypertriglyceridaemia, the mechanistic action of therapeutic agents, the interpretation of conflicting results on recent clinical trials, and the present options for primary and secondary prevention. The benefits of fibrates-induced reduction in TG and increase in high-density lipoprotein cholesterol might outweigh the disadvantages of increasing LDL-C levels in primary prevention. In secondary CVD prevention, using eicosapentaenoic acid without docosahexaenoic acid, in addition to statins, will be beneficial. This comprehensive review may prove useful for the development of novel approaches that target hypertriglyceridaemia in future.

引用

页码：570 / 582

页数：13

共 79 条

[1] Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease [J].

Abdelhamid, Asmaa S. ;

Brown, Tracey J. ;

Brainard, Julii S. ;

Biswas, Priti ;

Thorpe, Gabrielle C. ;

Moore, Helen J. ;

Deane, Katherine Ho ;

Summerbell, Carolyn D. ;

Worthington, Helen V. ;

Song, Fujian ;

Hooper, Lee .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (03)

[2] Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial [J].

Arai, Hidenori ;

Yamashita, Shizuya ;

Yokote, Koutaro ;

Araki, Eiichi ;

Suganami, Hideki ;

Ishibashi, Shun .

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (06) :521-538

[3] Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force [J].

Averna, Maurizio ;

Banach, Maciej ;

Bruckert, Eric ;

Drexel, Heinz ;

Farnier, Michel ;

Gaita, Dan ;

Magni, Paolo ;

Maerz, Winfried ;

Masana, Luis ;

Mello e Silva, Alberto ;

Reiner, Zeljko ;

Ros, Emilio ;

Vrablik, Michal ;

Zambon, Alberto ;

Zamorano, Jose L. ;

Stock, Jane K. ;

Tokgozoglu, Lale S. ;

Catapano, Alberico L. .

ATHEROSCLEROSIS, 2021, 325 :99-109

[4] PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021 [J].

Banach, Maciej ;

Burchardt, Pawl ;

Chlebus, Krzysztof ;

Dobrowolski, Piotr ;

Dudek, Dariusz ;

Dyrbus, Krzysztof ;

Gasior, Mariusz ;

Jankowski, Piotr ;

Jozwiak, Jacek ;

Klosiewicz-Latoszek, Longina ;

Kowalska, Irina ;

Malecki, Maciej ;

Prejbisz, Aleksander ;

Rakowski, Michat ;

Rysz, Jacek ;

Solnica, Bogdan ;

Sitkiewicz, Dariusz ;

Sygitowicz, Grazyna ;

Sypniewska, Grazyna ;

Tomasik, Tomasz ;

Windak, Adam ;

Zozulinska-Ziolkiewicz, Dorota ;

Cybulska, Barbara .

ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (06) :1447-1547

[5] Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia [J].

Bhatt, Deepak L. ;

Steg, P. Gabriel ;

Miller, Michael ;

Brinton, Eliot A. ;

Jacobson, Terry A. ;

Ketchum, Steven B. ;

Doyle, Ralph T., Jr. ;

Juliano, Rebecca A. ;

Jiao, Lixia ;

Granowitz, Craig ;

Tardif, Jean-Claude ;

Ballantyne, Christie M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) :11-22

[6] Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events A Meta-Analysis of Statin Trials [J].

Boekholdt, S. Matthijs ;

Hovingh, G. Kees ;

Mora, Samia ;

Arsenault, Benoit J. ;

Amarenco, Pierre ;

Pedersen, Terje R. ;

LaRosa, John C. ;

Waters, David D. ;

DeMicco, David A. ;

Simes, R. John ;

Keech, Antony C. ;

Colquhoun, David ;

Hitman, Graham A. ;

Betteridge, John ;

Clearfield, Michael B. ;

Downs, John R. ;

Colhoun, Helen M. ;

Gotto, Antonio M., Jr. ;

Ridker, Paul M. ;

Grundy, Scott M. ;

Kastelein, John J. P. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (05) :485-494

[7] Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial [J].

Budoff, Matthew J. ;

Bhatt, Deepak L. ;

Kinninger, April ;

Lakshmanan, Suvasini ;

Muhlestein, Joseph B. ;

Le, Viet T. ;

May, Heidi T. ;

Shaikh, Kashif ;

Shekar, Chandana ;

Roy, Sion K. ;

Tayek, John ;

Nelson, John R. .

EUROPEAN HEART JOURNAL, 2020, 41 (40) :3925-3932

[8] Using Multivariable Mendelian Randomization to Disentangle the Causal Effects of Lipid Fractions [J].

Burgess, Stephen ;

Freitag, Daniel F. ;

Khan, Hassan ;

Gorman, Donal N. ;

Thompson, Simon G. .

PLOS ONE, 2014, 9 (10)

[9] Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk [J].

Chapman, M. John ;

Redfern, Jan S. ;

McGovern, Mark E. ;

Giral, Philippe .

PHARMACOLOGY & THERAPEUTICS, 2010, 126 (03) :314-345

[10] Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk [J].

Das Pradhan, Aruna ;

Glynn, Robert J. ;

Fruchart, Jean-Charles ;

MacFadyen, Jean G. ;

Zaharris, Elaine S. ;

Everett, Brendan M. ;

Campbell, Stuart E. ;

Oshima, Ryu ;

Amarenco, Pierre ;

Blom, Dirk J. ;

Brinton, Eliot A. ;

Eckel, Robert H. ;

Elam, Marshall B. ;

Felicio, Joao S. ;

Ginsberg, Henry N. ;

Goudev, Assen ;

Ishibashi, Shun ;

Joseph, Jacob ;

Kodama, Tatsuhiko ;

Koenig, Wolfgang ;

Leiter, Lawrence A. ;

Lorenzatti, Alberto J. ;

Mankovsky, Boris ;

Marx, Nikolaus ;

Nordestgaard, Borge G. ;

Pall, Denes ;

Ray, Kausik K. ;

Santos, Raul D. ;

Soran, Handrean ;

Susekov, Andrey ;

Tendera, Michal ;

Yokote, Koutaro ;

Paynter, Nina P. ;

Buring, Julie E. ;

Libby, Peter ;

Ridker, Paul M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (21) :1923-1934

← 1 2 3 4 5 6 7 8 →